Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
subcutaneous drug delivery
Pharma
Halozyme sues Merck over subcutaneous Keytruda
Halozyme alleges in a lawsuit that a subcutaneous formulation of Merck’s popular cancer drug Keytruda infringes 15 of its patents.
Angus Liu
Apr 24, 2025 2:41pm
Merck lays out subcutaneous Keytruda data amid patent brawl
Mar 27, 2025 11:00am
AstraZeneca-Alteogen, Taiho, WuXi—Fierce Pharma Asia
Mar 21, 2025 9:10am
AstraZeneca inks $1.35B deal for subcutaneous cancer drugs
Mar 17, 2025 10:55am
Viking taps CordenPharma in $150M obesity drug production deal
Mar 11, 2025 10:25am
Merck, Halozyme dig in for patent fight over injectable Keytruda
Mar 6, 2025 11:18am
